In this issue:
Identifying systemic treatment candidates using IPC guidelines
Femoral atherosclerotic plaque in psoriasis patients
Home- vs office-based narrowband UV-B phototherapy
Safety and efficacy of deucravacitinib up to 3 years
Psoriasis risk with immune checkpoint inhibitors
Risankizumab for palmoplantar psoriasis
Age effects on drug survival rates of IL-17 and IL-23 inhibitors
Bimekizumab efficacy in scalp, nail, and palmoplantar psoriasis
Switching from ustekinumab to guselkumab in partial responders with psoriasis
Long-term efficacy and safety of biologics for plaque psoriasis
Please login below to download this issue (PDF)